Aimmune Licenses Exclusive Worldwide Rights to Xencors XmAb7195 for the Development of Next-Generati | AIMT Message Board Posts


Aimmune Therapeutics, Inc.

  AIMT website

AIMT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  60 of 65  at  2/6/2020 1:56:09 PM  by

jerrykrause


Aimmune Licenses Exclusive Worldwide Rights to Xencors XmAb7195 for the Development of Next-Generation Food Allergy Treatments

 
 
Pharma & Healthcare Monitor Worldwide
 
 

Aimmune Licenses Exclusive Worldwide Rights to Xencors XmAb7195 for the Development of Next-Generation Food Allergy Treatments

 

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb7195 to Aimmune Therapeutics, Inc.

XmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma. It uses three distinct mechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. Aimmune initially plans to develop AIMab7195 as an adjunctive treatment with select Characterized Oral Desensitized ImmunoTherapy (CODIT) programs, including PALFORZIA, to explore treatment outcomes in patients with food allergies.

As we look to the future of food allergy treatments, we are excited to explore the potential of oral immunotherapy to achieve greater levels of desensitization and perhaps even remission when combined with adjunctive biologics that target immune pathways, said Jayson Dallas, M.D., president and CEO of Aimmune. In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmunes global leadership in the evolving therapeutic landscape of food allergy treatments.

Aimmunes focus, clinical success and regulatory expertise in food allergy demonstrate their capability to advance AIMab7195 with highly complementary CODIT pipeline programs to create new options for people living with food allergy, said Bassil Dahiyat, Ph.D., President and CEO of Xencor. AIMab7195 is designed to reduce levels of IgE, a key mediator of allergic response, and there is strong scientific rationale that this reduction would synergize with the activity of desensitization therapies.

Under the terms of the agreement, Aimmune will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238 newly issued shares of Aimmune common stock at $32.00/share, the seven-day volume weighted average price. Xencor also is eligible to receive up to $385 million based on the achievement of certain clinical development, regulatory and commercialization milestones beginning with the initiation of a Phase 2 clinical trial and is eligible to receive a high single-digit to mid-teen percentage of royalties upon commercialization of AIMab7195. Aimmune will be solely responsible for costs related to the development of AIMab7195 and plans to provide a development plan in the coming months. 2020 Global Data Point.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 60 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...